BACKGROUND: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). PATIENTS AND METHODS: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan at 50 mg/m(2) on days 1 and 8 every four weeks for four cycles. RESULTS: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. CONCLUSION: Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.
BACKGROUND: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). PATIENTS AND METHODS: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan at 50 mg/m(2) on days 1 and 8 every four weeks for four cycles. RESULTS: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. CONCLUSION:Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.
Authors: Pier Luigi Filosso; Piero Ferolla; Francesco Guerrera; Enrico Ruffini; William D Travis; Giulio Rossi; Paolo Olivo Lausi; Alberto Oliaro Journal: J Thorac Dis Date: 2015-04 Impact factor: 2.895
Authors: James F Powers; Parimal G Korgaonkar; Stephanie Fliedner; Alessio Giubellino; Karel Pacak; G Gary Sahagian; Arthur S Tischler Journal: PLoS One Date: 2014-02-07 Impact factor: 3.240